343 related articles for article (PubMed ID: 15930273)
1. Functional analysis of PIK3CA gene mutations in human colorectal cancer.
Ikenoue T; Kanai F; Hikiba Y; Obata T; Tanaka Y; Imamura J; Ohta M; Jazag A; Guleng B; Tateishi K; Asaoka Y; Matsumura M; Kawabe T; Omata M
Cancer Res; 2005 Jun; 65(11):4562-7. PubMed ID: 15930273
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs.
Ross RL; Askham JM; Knowles MA
Oncogene; 2013 Feb; 32(6):768-76. PubMed ID: 22430209
[TBL] [Abstract][Full Text] [Related]
3. Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers.
Ikenoue T; Kanai F; Hikiba Y; Tanaka Y; Imamura J; Ohta M; Jazag A; Guleng B; Asaoka Y; Tateishi K; Kawakami T; Matsumura M; Kawabe T; Omata M
Mol Carcinog; 2005 May; 43(1):59-63. PubMed ID: 15791648
[TBL] [Abstract][Full Text] [Related]
4. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.
Ikenoue T; Hikiba Y; Kanai F; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Aragaki J; Matsumura M; Kawabe T; Omata M
Cancer Res; 2003 Dec; 63(23):8132-7. PubMed ID: 14678966
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
6. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression.
Guerrero S; Casanova I; Farré L; Mazo A; Capellà G; Mangues R
Cancer Res; 2000 Dec; 60(23):6750-6. PubMed ID: 11118062
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
Murugan AK; Hong NT; Fukui Y; Munirajan AK; Tsuchida N
Int J Oncol; 2008 Jan; 32(1):101-11. PubMed ID: 18097548
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation.
Menendez JA; Mehmi I; Verma VA; Teng PK; Lupu R
Mol Carcinog; 2004 Nov; 41(3):164-78. PubMed ID: 15390078
[TBL] [Abstract][Full Text] [Related]
9. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway.
Meng Q; Xia C; Fang J; Rojanasakul Y; Jiang BH
Cell Signal; 2006 Dec; 18(12):2262-71. PubMed ID: 16839745
[TBL] [Abstract][Full Text] [Related]
10. Mutation of the PIK3CA gene in anaplastic thyroid cancer.
García-Rostán G; Costa AM; Pereira-Castro I; Salvatore G; Hernandez R; Hermsem MJ; Herrero A; Fusco A; Cameselle-Teijeiro J; Santoro M
Cancer Res; 2005 Nov; 65(22):10199-207. PubMed ID: 16288007
[TBL] [Abstract][Full Text] [Related]
11. Hotspot mutations of PIK3CA and AKT1 genes are absent in multiple myeloma.
Ismail SI; Mahmoud IS; Msallam MM; Sughayer MA
Leuk Res; 2010 Jun; 34(6):824-6. PubMed ID: 20022634
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
[TBL] [Abstract][Full Text] [Related]
13. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase.
Carson JD; Van Aller G; Lehr R; Sinnamon RH; Kirkpatrick RB; Auger KR; Dhanak D; Copeland RA; Gontarek RR; Tummino PJ; Luo L
Biochem J; 2008 Jan; 409(2):519-24. PubMed ID: 17877460
[TBL] [Abstract][Full Text] [Related]
14. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract.
Riener MO; Bawohl M; Clavien PA; Jochum W
Genes Chromosomes Cancer; 2008 May; 47(5):363-7. PubMed ID: 18181165
[TBL] [Abstract][Full Text] [Related]
15. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
Hafner C; Landthaler M; Vogt T
Exp Dermatol; 2010 Aug; 19(8):e222-7. PubMed ID: 20557351
[TBL] [Abstract][Full Text] [Related]
16. Cancer-specific mutations in PIK3CA are oncogenic in vivo.
Bader AG; Kang S; Vogt PK
Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1475-9. PubMed ID: 16432179
[TBL] [Abstract][Full Text] [Related]
17. Both mitogen-activated protein kinase and phosphatidylinositol 3-kinase signalling are required in epidermal growth factor-induced human trophoblast migration.
Qiu Q; Yang M; Tsang BK; Gruslin A
Mol Hum Reprod; 2004 Sep; 10(9):677-84. PubMed ID: 15235105
[TBL] [Abstract][Full Text] [Related]
18. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
Klos KS; Wyszomierski SL; Sun M; Tan M; Zhou X; Li P; Yang W; Yin G; Hittelman WN; Yu D
Cancer Res; 2006 Feb; 66(4):2028-37. PubMed ID: 16489002
[TBL] [Abstract][Full Text] [Related]
19. PI3-kinase p110α mediates β1 integrin-induced Akt activation and membrane protrusion during cell attachment and initial spreading.
Zeller KS; Idevall-Hagren O; Stefansson A; Velling T; Jackson SP; Downward J; Tengholm A; Johansson S
Cell Signal; 2010 Dec; 22(12):1838-48. PubMed ID: 20667469
[TBL] [Abstract][Full Text] [Related]
20. Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity.
Bagli E; Stefaniotou M; Morbidelli L; Ziche M; Psillas K; Murphy C; Fotsis T
Cancer Res; 2004 Nov; 64(21):7936-46. PubMed ID: 15520200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
